Výsledky vyhledávání

Akademický článek

First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter study

Publikováno v: Frontiers in Oncology, Vol 14 (2024)

IntroductionPembrolizumab stands as a first-line option for patients with advanced non-small cell lung cancer (NSCLC) and high programmed death-ligand 1 (PD-L1) expression (PD-L1 ≥50%). Several factors such as antibiotic exposure, low body mass ind

Externí odkaz: https://doaj.org/article/5bddfd2fdb244305bbfcb2496d8d7880

Zobrazit plný text záznamu

Akademický článek

Walking one hour per day and the derived neutrophil-to-lymphocyte ratio are associated with outcome in palliative second-line immunotherapy for patients with recurrent and/or metastatic squamous cell carcinoma of head and neck

Autor: Miguel Caballero-Borrego, Aida Piedra, Óscar Gallego, Antonio López-Pousa, Paola Castillo, Pilar Navarrete, Alba Prat, Juan J. Grau

Publikováno v: Brazilian Journal of Otorhinolaryngology, Vol 90, Iss 6, Pp 101493- (2024)

Objectives: To determine whether routinary walking activity and the derived neutrophil-to-lymphocyte ratio are associated with outcomes in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Methods: This multicenter r

Externí odkaz: https://doaj.org/article/c20d13286a3f43beb6a7040b126aaf06

Zobrazit plný text záznamu

Akademický článek

Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 10, Iss 2 (2022)

Introduction It has been recognized that increasing body mass index (BMI) is associated with improved outcome from immune checkpoint inhibitors (ICIs) in patients with various malignancies including non-small cell lung cancer (NSCLC). However, it is

Externí odkaz: https://doaj.org/article/0d868f118ef644a68eebc13a655c68ba

Zobrazit plný text záznamu